Theravance Biopharma Inc - Company Profile
Powered by 
All the data and insights you need on Theravance Biopharma Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Theravance Biopharma Inc Strategy Report
- Understand Theravance Biopharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Theravance Biopharma Inc (Theravance Biopharma) is a biopharmaceutical company that discovers, develops, and markets organ-selective medicines for the treatment of inflammation and immune system disorders and specializes in developing respiratory medicines. The company is investigating its pipeline candidates for the treatment of asthma; and neurogenic orthostatic hypotension (nOH). Theravance Biopharma has agreements with other pharmaceutical companies and holds economic interests in potential future payments made to Innoviva, Inc from Glaxo Group Limited or one of its affiliates. The company has subsidiaries in the US, Ireland, and the UK. Theravance Biopharma is headquartered in George Town, Cayman Islands, the UK.
Headquarters
United Kingdom
Address
Ugland House, South Church Street, George Town, Cayman Islands, KY1-1104
Website
www.theravance.com
Telephone
1 345 6508086000
No of Employees
99
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TBPH (NASD)
Revenue (2022)
$57.4M
11.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-106.3%
(2022 vs 2021)
Market Cap*
$466.7M
Net Profit Margin (2022)
XYZ
-105.7%
(2022 vs 2021)
* As of and is in US$
Theravance Biopharma Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Yupelri (revefenacin): | YUPELRI |
| Inhalation Solution | |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Others | In September, the company announced a modified Dutch auction tender offer to purchase up to US$95 million of its ordinary shares, par value $0.00001 per share. |
| 2022 | Contracts/Agreements | In July, the company entered into a definitive agreement to sell all of its units in Theravance Respiratory Company, LLC. |
| 2022 | Official Trials/Tests | In January, the company announced enrollment of first patient in YUPELRI Phase 4 Study. |
Competitor Comparison
| Key Parameters | Theravance Biopharma Inc | Sanofi | Novartis AG | AstraZeneca Plc | Regeneron Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | France | Switzerland | United Kingdom | United States of America |
| City | George Town | Paris | Basel | Cambridge | Tarrytown |
| State/Province | Cayman Islands | Ile-de-France | - | England | New York |
| No. of Employees | 99 | 87,994 | 76,057 | 89,900 | 13,450 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Rick E. Winningham | Chief Executive Officer; Chairman | Executive Board | 2014 | 64 |
| Aziz Sawaf | Chief Financial Officer; Senior Vice President | Senior Management | 2023 | 42 |
| Stuart Knight | Vice President - IT&I; Chief Information Officer | Senior Management | 2020 | - |
| Rhonda F. Farnum | Chief Business Officer; Senior Vice President - Commercial and Medical Affairs | Senior Management | 2021 | 59 |
| Stacy Pryce | Chief Strategy Officer; Senior Vice President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward